EUVIMEDEUVIMED entdecken
Crossref

LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state

Xing Xia, Mei Ge, Junsheng Chen, Xiuping Qian, Daijie Chen, Yu Yin iD

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Xing Xia und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Vancomycin, Gram-Positive Bacteria, Drug Resistance, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Shaoxing Industrial R&D Program, National Key R&D Program of China, National Key Laboratory of Lead Druggability Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antibiotic resistance and tolerance pose dual challenges to clinical antibiotic therapy, with tolerance potentially accelerating resistance evolution. LYSC98, a candidate drug that has just received clinical approval in China, has been reported to have bactericidal activity against antibiotic-resistant Staphylococcus aureus. However, its mechanism and activity against antibiotic-resistant bacteria in tolerant state remains unexplored.

Objectives

To evaluate the antibacterial activity of LYSC98 against antibiotic-resistant bacteria in different metabolite states, and to elucidate its mechanism of action. Materials and methods MIC values of antimicrobial agents were determined using broth microdilution. Time–kill assays were used to evaluate the bactericidal effect. SEM and TEM were conducted to visualize the morphological changes. Membrane permeability was determined by propidium iodide.

Results

LYSC98 showed potent antibacterial activity against Gram-positive pathogens, with MICs ranging from 0.06 to 2 mg/L. It demonstrated a rapid bactericidal effect against antibiotic-resistant pathogens, irrespective of their growth phase or tolerant state, and conferred an extended post-antibiotic effect. Significantly, LYSC98 displayed a low potential for resistance development. It targeted both bacterial cell wall and membrane, with in vitro membrane assays indicating selective damage to these structures and no observed harm to mammalian cells.

Conclusions

LYSC98’s rapid bactericidal activity, selective disruption of bacteria without harming mammalian cells and low propensity for resistance development make it a novel promising candidate for combating chronic, clinically recalcitrant infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsVancomycinGram-Positive BacteriaDrug Resistance, BacterialMicrobial Sensitivity TestsMicrobial ViabilityCell MembraneCell WallCell Membrane PermeabilityHumansMicroscopy, Electron, TransmissionMicroscopy, Electron, Scanning

Substanzen

Anti-Bacterial AgentsVancomycin

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
  • National Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry, Shanghai 200120, China.
  • Research and Development Department, Shanghai Laiyi Center for Biopharmaceutical R&D, Shanghai 200240, China.

ORCID-Profile: Yu Yin

Förderung

  • Shaoxing Industrial R&D Program
  • National Key R&D Program of China
  • National Key Laboratory of Lead Druggability Research

Zitieren

APA

Xia, X., Ge, M., Chen, J., Qian, X., Chen, D., & Yin, Y. (2026). LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag036

Vancouver

Xia X, Ge M, Chen J, Qian X, Chen D, Yin Y. LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag036

BibTeX
@article{Xia2026,
  author = {Xia, Xing and Ge, Mei and Chen, Junsheng and Qian, Xiuping and Chen, Daijie and Yin, Yu},
  title = {LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag036}
}
Kostenlos starten →